This study, a single-center, open, single-dose clinical study, was designed to evaluate the safety and efficacy of IM96 CAR-T cells in treating patients with advanced adenocarcinoma of gastric/esophagogastric junction
The age is 18 to 75 years (including boundary values) and the gender is not limited;
Patients with advanced locally inoperable or metastatic adenocarcinoma of the stomach/gastric esophageal junction diagnosed by pathohistology;
Patients with metastatic stomach/gastric esophageal junction who have failed or are intolerant to standard therapy;
The standardized systemic treatment received by the patient must be in accordance with the Chinese Society of Clinical Oncology (CSCO) Guidelines for the Treatment of Gastric Cancer, 2025 Edition;
Presence of brain metastases;
Patients who have previously received or are awaiting an organ transplant;
Toxicity due to prior therapy not stabilized or recovered to ≤ grade 1 (except in cases judged by the investigator to be not clinically significant);
Plasmapheresis (e.g., pleural effusion, abdominal effusion, pericardial effusion) with symptoms of compression that cannot be controlled with treatment;
Beijing Immunochina Medical Science & Technology Co., Ltd.
Lead sponsor
Peking University Cancer Hospital & Institute
Collaborator